Twelve cycles of single-agent paclitaxel have been demonstrated to prolong pr ogression-free survival in women with advanced ovarian cancer whom achieved a c linical complete response to a primary platinum/paclitaxel chemotherapy reg-ime n. This trial was conducted to compare the toxicity and disease-free interval o f 3 cycles vs. 12 cycles of paclitaxel consolidation in patients treated with an intensive three-drug front-line regimen of carboplatin, paclitaxel, and gemci tabine. Following cytoreductive surgery, 26 ovarian cancer patients received pri mary chemotherapy with carboplatin (AUC = 5, day 1), paclitaxel (175 mg/m2 over 1 h, day 1), and gemcitabine (800 mg/m2, day 1 day 8), with treatment repeated e very 21 days ×6 cycles. The first 13 patients (group A) received three addition al cycles of paclitaxel (175 mg/m2 over 1 h every 21 days). The second set of 13 patients (group B) also received three cycles of paclitaxel (175 mg/m2 over 1 h every 21 days) and then received nine additional cycles of paclitaxel (135 mg/m2 over 1 h every 21 days) consolidation therapy. The change from 3 cycles to 12 cycles of consolidation therapy for group B was made following the published results of GOG 178. In group A, all 13 patients com pleted three courses of consolidation therapy. One patient experienced grade 3 n eutropenia and two patients exhibited both grade 4 neutropenia and thrombocytope nia. Grade ≥2 neuropathy developed in 3 patients (23%). In group B, 9 of the 1 3 patients whom were intended to receive 12 total cycles of paclitaxel consolida tion were able to complete the program. There was no grade 3-4 neutropenia or a nemia in this population, although 1 patient developed grade 3 thrombocytopenia. Grade ≥2 neuropathy developed in 7 patients (54%). Although not a randomized experience, median progression-free interval was 76 weeks for group B, and 47 w eeks for group A. Sin-gle-agent paclitaxel consolidation therapy can be admini stered for 12 cycles following first-line carboplatin, paclitaxel, and gemcitab ine induction therapy, but there is considerable risk for development of a moder ately severe peripheral neuropathy. Twelve cycles of single-agent paclitaxel have been demonstrated to prolong pr ogression-free survival in women with advanced ovarian cancer whom achieved ac linical complete response to a primary platinum / paclitaxel chemotherapy reg-ime n. This trial was to to compare the toxicity and disease-free interval of 3 cycles vs. 12 cycles of paclitaxel consolidation in patients treated with an intensive three-drug front-line regimen of carboplatin, paclitaxel, and gemci tabine. Following cytoreductive surgery, 26 ovarian cancer patients received pri mary chemotherapy with carboplatin (AUC = 5, day 1), paclitaxel (175 mg / m2 over 1 h, day 1), and gemcitabine (800 mg / m2 day 1 day 8) with treatment repeated e very 21 days × 6 cycles. 13 patients (group A) received three additions of cycles of paclitaxel (175 mg / m2 over 1 h every 21 days). The second set of 13 patients (group B) also received three cycles of paclitaxel (175 mg / m2 over 1 h every 21 days) and then received nine a The change from 3 cycles to 12 cycles of consolidation therapy for group B was made the following the published results of GOG 178. In group A, all 13 patients One patient experienced grade 3 n eutropenia and two patients exhibited both grade 4 neutropenia and thrombocytope nia. Grade ≧ 2 neuropathy developed in 3 patients (23%). In group B, 9 of the 1 3 patients There were no grade 3-4 neutropenia or a nemia in this population, although 1 patient developed grade 3 thrombocytopenia. Grade ≥2 neuropathy developed in 7 patients (54%). Not a randomized experience, median progression-free interval was 76 weeks for group B, and 47 w eeks for group A. Sin-gle-agent paclitaxel consolidation therapy can be admini stered for 12 cycles followi ng first-line carboplatin, paclitaxel, and gemcitab ine induction therapy, but there is considerable risk for the development of a moder ately severe peripheral neuropathy.